NEW YORK (GenomeWeb) – The University of Texas MD Anderson Cancer Center and Guardant Health said today that they are entering a multi-year partnership that they hope will help accelerate the translation of Guardant's liquid biopsy technology into a standard-of-care tool for guiding the treatment of cancer patients.

Under the terms of the partnership, Guardant will help MD Anderson build multiple on-site liquid biopsy centers in which the center will develop new assays using Guardant's cell-free DNA-sequencing technology.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Atlantic reports that genetic counselors are coping with an influx of patients seeking advice on their direct-to-consumer genetic test results.

A small study finds differences between three genomic prostate cancer tests, Medscape reports.

In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.

A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.